BHI THERAPEUTIC SCIENCES SCIENTIFIC ADVISORY BOARD CHAIRMAN RECEIVES APPROVAL TO USE STEM CELL PRODUCT IN CLINICAL TRIALS

Posted by on Feb 4, 2020 in news | 0 comments

A Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) product, developed by Wuhan Hamilton Biotechnology Co., Ltd., recently passed inspection by the China National Institute for Food and Drug Control. As a result, the UC-MSCs are a qualified product for application in clinical trials.

Dongecheng Wu, MD, Ph.D., manager and chief scientist of Wuhan Hamilton Biotechnology Co., Ltd. and his team will begin a study entitled “Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis.” Dr. Wu is also the chairman of the Scientific Advisory Board of BHI Therapeutic Sciences. 

“Stem cells have been shown to migrate to sites of injury and inflammation where they are believed to support the survival of damaged cell and inhibit the immune responses,” said Dr. Wu. “Stem cell application in clinical trials shows promising results in therapy of neurological, musculoskeletal, cardiovascular and metabolic diseases,” he added.

The study will be conducted at Union Hospital, Tongji Medical College Huazhing University of Science and Technology. This study is the first clinical research project registered in Hubei Province with the China Medical Biotechnology Association.

Brian Mehling, MD, founder and chief medical officer of the BHI Therapeutic Sciences and long-time scientific partner with Dr. Wu, said “Stem cell research is the most exciting option in the field of regenerative medicine being tested for efficacy in treating a variety of health issues where the body’s own response to traditional treatment isn’t sufficient to restore health and optimum function.”

“Together with Dr. Wu, we are focused on bringing advanced stem cell therapies within reach of a wider audience, “said Dr. Mehling. We envision a future in which stem cells are preferred over many surgical, pharmacological, and rehabilitative medical services,” he added. 

Dr. Mehling is a practicing American orthopedic trauma surgeon, researcher, and member of the prestigious International Society for Stem Cell Research. He is spearheading groundbreaking research in stem cell therapy focused on treatment and research using stem cells.

Dr. Wu is a Professor at Wuhan University School of Basic Medical Science and a Chu Tian Scholar.BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells.   Its stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice. Results show its cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions. Multiple studies of umbilical cord blood derived stem cell therapies and adipose-derived stem cell therapies are currently under investigation in clinical trials for a wide-range of medical conditions and show promising results. The Food and Drug Administration (FDA) has given BHITS approval to proceed with an Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke. For more information, please visit www.bhisciences.com

Leave a Reply

Your email address will not be published.